29 August 2018
McCann FitzGerald advises Adapt Pharma and its Shareholders on its Sale to Emergent Biosolutions Inc.
We are advising Adapt Pharma, the Irish company which is the distributor of NARCAN® (naloxone HCl) Nasal Spray, and it shareholders on the sale of Adapt Pharma to Emergent BioSolutions Inc. for up to $735 million in cash and shares.
NARCAN® is an FDA approved treatment for the reversal of opioid overdose and plays a critical role in responding to the opioid crisis
McCann FitzGerald has acted for Adapt Pharma since it was first established.
Select how you would like to share using the options below